List view / Grid view
New data on Selincro from three phase III studies that…
8 April 2013 | By H. Lundbeck A/S
New data on Selincro from three phase III studies that show a significant reduction in alcohol consumption in alcohol dependent patients with high risk drinking level...
Results add to evidence for Azilect as an effective and…
20 March 2013 | By H. Lundbeck A/S
Results add to evidence for Azilect as an effective and well-tolerated treatment option at different stages of the progression of PD...
Lundbeck took first place in a global survey, in which…
14 January 2013 | By H. Lundbeck A/S
Lundbeck took first place in a global survey, in which 600 patient groups around the world evaluated the ability of 29 pharmaceutical companies to meet patient expectations...
The pivotal clinical programme is in planning...
29 May 2012 | By H. Lundbeck A/S
The pivotal clinical programme is in planning...
H. Lundbeck A/S announced positive top-line results from three recently…
14 May 2012 | By H. Lundbeck A/S
H. Lundbeck A/S announced positive top-line results from three recently completed phase III clinical studies of Lu AA21004...
Lu AA21004 may have positive effect on cognitive dysfunction in…
8 May 2012 | By H. Lundbeck A/S
Lu AA21004 may have positive effect on cognitive dysfunction in patients with major depressive disorders...
H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka)…
7 May 2012 | By H. Lundbeck A/S
H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced results from a clinical phase III clinical trial evaluating the efficacy, safety and tolerability of once-monthly aripiprazole intramuscular (IM) depot formulation for the maintenance treatment of adults with schizophrenia. Trial results were presented in four poster presentations at…
Lundbeck acquires Paion's remaining rights to desmoteplase for EUR 20.1…
28 February 2012 | By H. Lundbeck A/S (Lundbeck)
Lundbeck acquires Paion's remaining rights to desmoteplase for EUR 20.1 million thereby further strengthening the control over desmoteplase...
Lundbeck has appointed Jens Peter Balling and Iman Barilero as…
28 October 2011 | By H. Lundbeck A/S
Lundbeck has appointed Jens Peter Balling and Iman Barilero as vice presidents in its research and development organisation...
The FDA has approved Onfi™ (clobazam)...
24 October 2011 | By H. Lundbeck A/S
The FDA has approved Onfi™ (clobazam)...
